China SXT Pharmaceuticals, Inc. (SXTC) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2026, filed Jul 1, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SXTC SEC filings page.
China SXT Pharmaceuticals, Inc. (SXTC) reported $1.1M in revenue for fiscal year 2026, down 34.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The sales base is shrinking, and external financing is increasingly carrying a business whose overhead overwhelms gross profit.
Sales contraction took revenue from$2.6M in FY2022 to$1.1M in FY2026. By FY2026, gross-margin compression had reduced the contribution per sale to21.9% , so weaker volume was compounded by weaker unit economics.
The latest net loss was
Total assets rose to
Financial Health Signals
Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of China SXT Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
China SXT Pharmaceuticals, Inc. held $28.2M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations used $4.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and China SXT Pharmaceuticals, Inc. scores 74/100 among other emerging companies.
Not available for China SXT Pharmaceuticals, Inc., and counted as zero in the overall score.
Not available for China SXT Pharmaceuticals, Inc., and counted as zero in the overall score.
China SXT Pharmaceuticals, Inc. reported revenue of $1.1M in fiscal year 2026, against $1.7M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and China SXT Pharmaceuticals, Inc. scores 16/100 among other emerging companies.
China SXT Pharmaceuticals, Inc.'s operations used $4.0M of cash in fiscal year 2026, against $2.3M used in fiscal year 2025. Burn Trend ranks emerging companies on which way that figure has moved over three years, and China SXT Pharmaceuticals, Inc. scores 18/100 among other emerging companies.
China SXT Pharmaceuticals, Inc.'s cash, cash equivalents and investments came to $28.2M at the end of fiscal year 2026, against $5.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and China SXT Pharmaceuticals, Inc. scores 90/100 among other emerging companies.
China SXT Pharmaceuticals, Inc. scores -0.97, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($102K) relative to total liabilities ($5.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
China SXT Pharmaceuticals, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
China SXT Pharmaceuticals, Inc. reported a net loss of $6.2M while operations used $4.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
China SXT Pharmaceuticals, Inc. reported an operating loss of $7.1M against $63K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2026.
Cash & Balance Sheet
China SXT Pharmaceuticals, Inc. held $28.2M in cash against $644K in long-term debt as of Q4 2026.
Not reported for Q4 2026.
Not reported for Q4 2026.
Margins & Returns
None of these metrics is reported for Q4 2026.
Capital Allocation
None of these metrics is reported for Q4 2026.
SXTC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
SXTC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2620-F | Q2'2610-Q | Q4'2520-F | Q2'2510-Q | Q4'2420-F | Q2'2410-Q | Q4'2310-K | Q2'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $34.8M+60.4% | $26.4M-15.0% | $21.7M-6.3% | $31.0M+112.5% | $23.1M-21.7% | $14.6M-34.2% | $29.6M-11.9% | $22.2M-2.2% |
| Current Assets | $34.5M+62.0% | $26.0M+18.4% | $21.3M+49.6% | $22.0M+62.9% | $14.2M-27.1% | $13.5M+9.2% | $19.5M-13.1% | $12.4M+6.0% |
| Cash & Equivalents | $28.2M+55.7% | $21.2M+14.3% | $18.1M+49.9% | $18.5M+61.5% | $12.1M-30.5% | $11.5M+284.6% | $17.4M+11.9% | $3.0M+9417.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $777K-6.2% | $751K-13.4% | $828K+4.2% | $867K+75.8% | $795K+49.6% | $493K-21.5% | $531K-47.8% | $628K-25.0% |
| Accounts Receivable | $932K-28.4% | $1.3M-19.7% | $1.3M-1.0% | $1.7M+26.9% | $1.3M-2.2% | $1.3M-60.5% | $1.3M-59.7% | $3.3M-14.4% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $5.0M-18.9% | $6.1M-61.7% | $6.2M-32.3% | $16.0M+67.8% | $9.2M-38.1% | $9.5M+30.4% | $14.9M-13.2% | $7.3M-17.9% |
| Current Liabilities | $4.3M-27.7% | $6.0M-61.9% | $6.0M-32.5% | $15.7M+70.3% | $8.9M-38.6% | $9.2M+26.2% | $14.5M-15.3% | $7.3M-17.9% |
| Non-Current Liabilities | $698K+229.7% | $158K-46.9% | $212K-28.2% | $298K-4.3% | $295K-19.5% | $312K | $366K | $0 |
| Long-Term Debt | $644K+569.4% | $73K-36.6% | $96K-17.8% | $115K+8.2% | $117K-0.6% | $107K | $118K | N/A |
| Total Equity | $29.7M+92.4% | $20.2M+34.6% | $15.4M+10.8% | $15.0M+196.2% | $13.9M-5.2% | $5.1M-65.1% | $14.7M-8.7% | $14.5M+5.5% |
| Retained Earnings | -$34.2M-22.1% | -$34.4M-34.8% | -$28.0M-13.4% | -$25.5M+18.5% | -$24.7M-14.3% | -$31.3M-82.2% | -$21.6M-37.8% | -$17.2M-31.7% |
Not reported in any period shown, so not listed: Goodwill.
SXTC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
SXTC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| China SXT Pharmaceuticals, Inc. SXTC | FY2026 | $1.1M | -$6.2M | N/A | $102K | 33/100 |
| Ironwood Pharmaceuticals, Inc. IRWD | FY2025 | $296.2M | $24.0M | 8.1% | $631.2M | 34/100 |
| Journey Medical Corporation DERM | FY2025 | $61.9M | -$11.4M | -18.5% | $178.1M | 20/100 |
| Alpha Teknova, Inc. TKNO | FY2025 | $40.5M | -$17.3M | -42.6% | $474.6M | 48/100 |
| BioAge Labs, Inc. BIOA | FY2025 | $9.0M | -$80.6M | N/A | $291.0M | 46/100 |
Where China SXT Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
What is China SXT Pharmaceuticals, Inc.'s annual revenue?
China SXT Pharmaceuticals, Inc. (SXTC) reported $1.1M in total revenue for fiscal year 2026. This represents a -34.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is China SXT Pharmaceuticals, Inc.'s revenue growing?
China SXT Pharmaceuticals, Inc. (SXTC) revenue declined by 34.6% year-over-year, from $1.7M to $1.1M in fiscal year 2026.
Is China SXT Pharmaceuticals, Inc. profitable?
No, China SXT Pharmaceuticals, Inc. (SXTC) reported a net income of -$6.2M in fiscal year 2026.
What is China SXT Pharmaceuticals, Inc.'s EBITDA?
China SXT Pharmaceuticals, Inc. (SXTC) had EBITDA of -$7.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does China SXT Pharmaceuticals, Inc. have?
As of fiscal year 2026, China SXT Pharmaceuticals, Inc. (SXTC) had $28.2M in cash and equivalents against $644K in long-term debt.
What is China SXT Pharmaceuticals, Inc.'s gross margin?
China SXT Pharmaceuticals, Inc. (SXTC) had a gross margin of 21.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is China SXT Pharmaceuticals, Inc.'s return on equity (ROE)?
China SXT Pharmaceuticals, Inc. (SXTC) has a return on equity of -20.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is China SXT Pharmaceuticals, Inc.'s operating cash flow?
China SXT Pharmaceuticals, Inc. (SXTC) recorded an outflow of $4.0M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are China SXT Pharmaceuticals, Inc.'s total assets?
China SXT Pharmaceuticals, Inc. (SXTC) had $34.8M in total assets as of fiscal year 2026, including both current and long-term assets.
What is China SXT Pharmaceuticals, Inc.'s current ratio?
China SXT Pharmaceuticals, Inc. (SXTC) had a current ratio of 7.93 as of fiscal year 2026, which is generally considered healthy.
What is China SXT Pharmaceuticals, Inc.'s debt-to-equity ratio?
China SXT Pharmaceuticals, Inc. (SXTC) had a debt-to-equity ratio of 0.02 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is China SXT Pharmaceuticals, Inc.'s return on assets (ROA)?
China SXT Pharmaceuticals, Inc. (SXTC) had a return on assets of -17.8% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is China SXT Pharmaceuticals, Inc.'s P/E ratio?
China SXT Pharmaceuticals, Inc. (SXTC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $102K as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is China SXT Pharmaceuticals, Inc.'s price-to-sales ratio?
China SXT Pharmaceuticals, Inc. (SXTC) trades at 0.1x sales, its market capitalization divided by revenue of $1.1M revenue, FY2026. The market capitalization is $102K as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does China SXT Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, China SXT Pharmaceuticals, Inc. (SXTC) held $28.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.0M over that year. Dividing the one by the other, the reported balance equals about 84 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is China SXT Pharmaceuticals, Inc.'s Altman Z-Score?
China SXT Pharmaceuticals, Inc. (SXTC) has an Altman Z-Score of -0.97, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is China SXT Pharmaceuticals, Inc.'s Piotroski F-Score?
China SXT Pharmaceuticals, Inc. (SXTC) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are China SXT Pharmaceuticals, Inc.'s earnings high quality?
China SXT Pharmaceuticals, Inc. (SXTC) reported a net loss of $6.2M while operations used $4.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can China SXT Pharmaceuticals, Inc. cover its interest payments?
China SXT Pharmaceuticals, Inc. (SXTC) reported an operating loss of $7.1M against $63K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is China SXT Pharmaceuticals, Inc.?
China SXT Pharmaceuticals, Inc. (SXTC) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.